Table 1.
Baseline characteristics.
| Rosuvastatin | Rosuvastatin/Ezetimibe | ||
|---|---|---|---|
| Parameters | N=74 | N=75 | p value |
| Age (years) | 56.9 ± 11.1 | 53.6 ± 12.4 | 0.091 |
| Sex, male | 33 (44.6%) | 35 (46.7%) | 0.464 |
| BMI (kg/m2) | 25.2 ± 4.6 | 26.0 ± 4.1 | 0.250 |
| T2DM duration (years) | 6.2 ± 7.1 | 4.9 ± 6.4 | 0.233 |
| HbA1c (%) | 7.2 ± 1.6 | 7.0 ± 1.4 | 0.287 |
| Insulin (μIU/ml) | 14.38 ± 8.82 | 18.20 ± 14.28 | 0.103 |
| C-peptide (ng/ml) | 1.52 ± 0.60 | 1.74 ± 1.16 | 0.614 |
| HOMA-IR | 5.8 ± 3.7 | 7.2 ± 6.4 | 0.200 |
| HOMA-β (%) | 92.6 ± 96.3 | 89.5 ± 72.5 | 0.860 |
| Triglyceride (mg/dL) | 165.8 ± 91.7 | 178.0 ± 97.7 | 0.435 |
| Total cholesterol (mg/dL) | 213.9 ± 26.5 | 213.5 ± 32.7 | 0.936 |
| HDL-C (mg/dL) | 51.8 ± 13.2 | 48.5 ± 12.3 | 0.116 |
| LDL-C (mg/dL) | 137.4 ± 23.4 | 136.1 ± 23.2 | 0.739 |
| BUN (mg/dL) | 16.1 ± 4.6 | 15.1 ± 4.2 | 0.166 |
| Creatinine (mg/dL) | 0.72 ± 0.19 | 0.72 ± 0.18 | 0.946 |
| eGFR (mL/min/1.732m2) | 98.3 ± 16.2 | 99.2 ± 19.1 | 0.749 |
| hsCRP (mg/dL) | 2.1 ± 3.8 | 1.8 ± 2.3 | 0.581 |
BMI, body mass index; T2DM, type 2 diabetes mellitus; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of beta cell function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein. Data are presented as mean ± SD or number (corresponding proportion in percentage).